“The unveiling of Revvity is the capstone of a nearly year-long journey that has transformed who we are and reinforces why our work matters”

“The unveiling of Revvity is the capstone of a nearly year-long journey that has transformed who we are and reinforces why our work matters,” said Prahlad Singh, president and chief executive officer of Revvity. “At Revvity, we are united with our customers to impact health across the lifespan. Our purpose is to expand the boundaries of human potential through science. We view the challenges facing our customers as a call to action.”

Revvity provides reagents, consumables, assays, instruments and software to customers in markets ranging from pharma and biotech, diagnostic labs, academia and government agencies. “We’re a translational company in the sense that our capabilities facilitate decision making between research and clinical customers,” remarked Singh. “With cross-business collaborations between our automation, multi-omics offerings, and our Signals software business, we have unique capabilities which put us in an optimal position to accelerate breakthrough solutions – starting with preclinical research and scientific discovery, all the way through to diagnosing and helping to treat disease.”

Changes to Brand Architecture

• Industry leading franchises, BioLegend, EUROIMMUN, Tulip Diagnostics and ViaCord retain their own names as unique product lines.
• The Company’s comprehensive scientific software platform, previously known as PerkinElmer Informatics, will become Revvity Signals Software, Inc.
• Revvity Omics replaces PerkinElmer Genomics as the Company's genomics services business.
• Cisbio, Horizon Discovery, Nexcelom Bioscience, Omni International, Oxford Immunotec, SIRION Biotech and SonoVol will now identify as Revvity, while maintaining their specific product names.